Patents Examined by Julie Burke
  • Patent number: 6372884
    Abstract: A method of constructing biologically active compounds which mimic the biological activity of the biologically active protein block the activity of the biologically active protein is disclosed. A method of identifying specific and discrete portions of pathogen antigens which either serve as epitopes for neutralizing antibodies or which are involved in pathogen binding to host cell receptors is disclosed. A method of constructing biologically active compounds which compete with cellular receptors for binding to either biologically active proteins or pathogen antigens is disclosed.
    Type: Grant
    Filed: November 21, 1996
    Date of Patent: April 16, 2002
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Mark I. Greene, William V. Williams, David B. Weiner, Jeffrey A. Cohen, Thomas Kieber-Emmons, Robert M. Williams
  • Patent number: 6258942
    Abstract: The invention is a protein having the amino acid sequence of Seq. I.D. No. 1 or an allelic variation retaining the biological activity of the protein having the amino acid sequence of Seq. I.D. No. 1, a DNA segment coding for a protein according to claim 1, preferably DNA segment according to claim 2 having the sequence of Seq. I.D. No. 2, or a substitution analog or allelic variation of Seq. I.D. No. 2, a chimeric cell comprising the DNA segment coding for a protein of Seq. I.D. No. 1, preferably a chimeric cell comprising the DNA segment of Seq. I.D. No. 2, a vector comprising a DNA segment coding for a protein having Seq. I.D. No. 1 operably linked to a promoter. The invention provides a preferred vector comprising the following components operably linked from 5′ to 3′: (a) a promoter; (b) a signal sequence; (c) 5′ portion of a highly expressed gene endogenous to a selected host cell; (d) a linker sequence; all preceding the nucleotide sequence coding for TADG7 protein.
    Type: Grant
    Filed: September 9, 1997
    Date of Patent: July 10, 2001
    Assignee: The Board of Trustees of the University of Arkansas
    Inventors: Timothy J. O'Brien, Sung Moon
  • Patent number: 6231850
    Abstract: Canine interleukin 12 and a method for producing it by genetic engineering are disclosed. The canine interleukin 12 includes a protein having an amino acid sequence substantially the same as SEQ ID NO:1 or SEQ ID NO:11 or corresponds to part of either of SEQ ID NOS:1 and 11, and a protein having an amino acid sequence substantially the same as SEQ ID NO:2 or SEQ ID NO:12 or corresponds to part of either of SEQ ID NOS:2 and 12, and relates to a production method thereof. There is also an immune disease remedy and preventive agent for dogs and cats containing canine interleukin 12, and a method of treating immune disease and a preventive method for dogs and cats using the immune disease remedy or preventive agent.
    Type: Grant
    Filed: May 15, 1998
    Date of Patent: May 15, 2001
    Assignee: Toray Industries, Inc.
    Inventors: Fumiyoshi Okano, Masahiro Satoh, Katsushige Yamada
  • Patent number: 6221622
    Abstract: Methods, kits, and apparatus for obtaining cellular, chemical, and other materials from breast ducts are described. A single milk duct is accessed and washed with a washing fluid to obtain marker materials from the lining the duct. The washing fluid is then collected, and the marker materials in the washing fluid identified and analyzed. Usually, the washing fluid is introduced using a syringe through a lumen of a dual-lumen catheter. The ductal volume is filled with the washing fluid and excess fluid flows outwardly through a second lumen of the dual-lumen catheter, from which it is collected.
    Type: Grant
    Filed: April 28, 1998
    Date of Patent: April 24, 2001
    Assignee: The Regents of the University of California
    Inventor: Susan M. Love
  • Patent number: 6207812
    Abstract: The invention features a nucleic acid molecule encoding a chondrosarcoma associated polypeptide and methods for diagnosing patients with chondrosarcoma. the gene.
    Type: Grant
    Filed: March 13, 1998
    Date of Patent: March 27, 2001
    Assignee: Rhode Island Hospital
    Inventor: Richard M. Terek
  • Patent number: 6204023
    Abstract: The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts tansformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains. The invention also relates to DNA coding for pectate lyase signal peptide has been cloned on a plasmid to create a secretion vector which is capable of producing a chosen protein which is transported across the bacterial membrane. The secretion vector has been used to secrete extracellular thaumatin and extracellular chimeric antibody fragments. The proteins produced by this vector have biological activity. The thaumatin is properly folded and the antibody fragments are capable of binding antigens on target cancer cells.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 20, 2001
    Assignee: XOMA Ltd.
    Inventors: Randy R. Robinson, Alvin Y. Liu, Arnold H. Horwitz, Marc Better, Randolph Wall, Shau-Ping Lei, Gary L. Wilcox
  • Patent number: 6204366
    Abstract: A reshaped human antibody or reshaped human antibody fragment having specificity for human polymorphic epithelial mucin (PEM) is produced by transferring the complementarity determining regions (CDRS) from a murine anti-HMFG hybridoma cell line HMFG1 into a human antibody variable region framework. The reshaped molecule can be used in the treatment or diagnosis of cancer.
    Type: Grant
    Filed: May 7, 1993
    Date of Patent: March 20, 2001
    Assignee: Unilever Patent Holdings B.V.
    Inventor: Martine Elisa Verhoeyen
  • Patent number: 6193969
    Abstract: A method of neutralizing TNF&agr; in a patient benefiting from such neutralizing, comprising administering to the patient IgG Fab fragment reactive towards TNF&agr;. Suitably, the patient is suffering from septic shock or from the symptoms of septic shock. It is preferred if the Fab fragment is derived from polyclonal IgG.
    Type: Grant
    Filed: March 10, 1995
    Date of Patent: February 27, 2001
    Assignee: Protherics Inc.
    Inventor: John Landon
  • Patent number: 6180357
    Abstract: The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies customized for the individual patient that can be used for therapeutic and diagnostic purposes. The invention further relates to the process by which the antibodies are made and to their methods of use. The antibodies can be made specifically for one tumor derived from a particular patient and are selected on the basis of their cancer cell cytotoxicity and simultaneous lack of toxicity for non-cancerous cells. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat tumor metastases.
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: January 30, 2001
    Assignee: Arius Research, Inc.
    Inventors: David S. F. Young, Miyoko Takahashi
  • Patent number: 6180370
    Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 30, 2001
    Assignee: Protein Design Labs, Inc.
    Inventors: Cary L. Queen, Harold E. Selick
  • Patent number: 6166176
    Abstract: A cDNA molecule that encodes a protein designated Labyrinthin (Lab) is isolated and its nucleotide sequence is determined. The protein, or peptides derived from the protein, are markers useful to define novel classes of cancers. Diagnostic assays for these cancers use antibodies to Lab or nucleotide probes that hybridize with the lab gene or a fragment therefrom. Vaccines useful either to prevent recurrence of cancers in subjects who test positive for Lab (or lab), or to prevent initial occurrence of cancer, use proteins or peptides derived from Lab. Expression of Lab via immunogenic assays is used to monitor effects of cancer treatments. Antisense molecules against lab are used in treatments. Sense molecules of lab are used to restore lost lab function in diseased normal cells, for example, gland cells.
    Type: Grant
    Filed: March 17, 1998
    Date of Patent: December 26, 2000
    Assignee: ImmvaRx, Inc.
    Inventor: James A. Radosevich
  • Patent number: 6150398
    Abstract: A pharmaceutical composition comprising an effective cancerous cell growth inhibiting amount of paclitaxel, or a paclitaxel derivative, and an effective cancerous cell growth inhibiting amount of an active agent which inhibits cancerous cell growth by exerting an effect on mammalian cell cycle during G.sub.1 or S-phase of the cell division cycle to inhibit said cancerous cell growth and methods of using same.
    Type: Grant
    Filed: March 20, 1996
    Date of Patent: November 21, 2000
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: George F. Vande Woude, Nicholas Schulz, Renping Zhou, Ira Daar, Marianne Oskarsson
  • Patent number: 6140468
    Abstract: The present invention relates to the production and purification of human prostate specific antigen (hPSA) by recombinant-DNA-technology. hPSA was produced in an active form by the baculovirus expression vector system. Recombinant protein was secreted into the culture medium at a high yield by infected cells and purified to homogeneity by three-step procedure containing cation-exchange chromatography and gel filtration. The active protein obtained differs from the native protein in that it is unglycosylated and that it does not degrade the kallikrein-specific substrate H-D-Pro-Phe-Arg-pNA.HCl. The inactive form of hPSA obtained has two additional amino acid residues in its N-terminus, and it does not form complexes. Possible uses of the recombinant protein are also disclosed.
    Type: Grant
    Filed: December 29, 1997
    Date of Patent: October 31, 2000
    Assignee: Boehringer Mannheim GmbH
    Inventor: Pirkko Vihko
  • Patent number: 6135941
    Abstract: The invention provides human immune system associated proteins (HISAP) and polynucleotides which identify and encode HISAP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HISAP.
    Type: Grant
    Filed: March 27, 1998
    Date of Patent: October 24, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Preeti Lal, Y. Tom Tang, Henry Yue, Janice Au-Young, Neil C. Corley, Karl J. Guegler, Mariah R. Baughn
  • Patent number: 6130322
    Abstract: This invention is directed to the isolated coding sequences and to the protein sequences they code for. This invention is directed to three coding sequence of the BRCA1 gene. The three coding sequences, BRCA1.sup.(omi1), BRCA1.sup.(omi2), and BRCA1.sup.(omi3) and their frequencies of occurrence are provided together with the protein sequences they code for. Another aspect of this invention is a method of determining the consensus sequence for any gene. Another aspect of the invention is a method of identifying an individual having an increased genetic susceptibility to breast or ovarian cancer because they have inherited a causative mutation in their BRCA1 gene. This invention is also related to a method of performing gene therapy with any of the isolated BRCA1 coding sequences. This invention is further related to protein therapy with BRCA.sup.(omi) proteins or their functional equivalent.
    Type: Grant
    Filed: May 6, 1998
    Date of Patent: October 10, 2000
    Assignee: Gene Logic, Inc.
    Inventors: Patricia D. Murphy, Antonette C. P. Allen, Christopher P. Alvares, Brenda S. Critz, Sheri J. Olson, Denise Thurber, Bin Zeng
  • Patent number: 6127524
    Abstract: The present invention features novel binding molecules and methods of improving the specific binding affinity of binding molecules, which methods do not use X-ray crystallography. For example, in one aspect, the invention features methods of making antibodies with improved specific binding affinity for a polypeptide produced during prothrombin activation. The present invention is useful for a variety of applications including, e.g., producing binding molecules with improved binding affinity; and screening for binding molecules which are in low abundance.
    Type: Grant
    Filed: October 18, 1996
    Date of Patent: October 3, 2000
    Assignee: Dade Behring Inc.
    Inventors: Clayton L. Casipit, Hing C. Wong, Bee Y. Huang
  • Patent number: 6117985
    Abstract: The present invention relates to antibody composition that are useful in preparing enriched cell preparations such as human hematopoietic progenitor cells and stem cells and non-hematopoietic tumor cells. The invention also relates to kits for carrying out the processes and to the cell preparations prepared by the processes.
    Type: Grant
    Filed: June 1, 1998
    Date of Patent: September 12, 2000
    Assignee: Stemcell Technologies Inc.
    Inventors: Terry Thomas, Peter Lansdorp
  • Patent number: 6106833
    Abstract: This invention relates generally to the field of immunology, in particular that of antibodies and antibody productions. More specifically, this invention relates to bispecific antibodies, the hybrid hybridomas which produce them, the parent hybridomas, the production and selection of the hybridomas and hybrid hybridomas, and the purification of the bispecific antibodies. Specific examples relate to bispecific monoclonal antibodies which recognize both the human multi-drug resistance antigen, P-glycoprotein and human Fc.gamma. receptor III (hFc.gamma.RIII). These bispecific antibodies are useful in killing cancer cells.
    Type: Grant
    Filed: November 12, 1997
    Date of Patent: August 22, 2000
    Assignee: Chiron Corporation
    Inventors: David Ring, Tian-Xiang Shi
  • Patent number: 6103233
    Abstract: First and second compounds are provided, where the first compound is administered to a mammalian host into blood for covalent bonding to blood components, where the components have an extended lifetime in the blood stream. The first compound comprises an active functionality and an agent of interest or a first binding entity. A second compound may be subsequently administered to the patient, which comprises a second binding entity, complementary to the first binding entity and an agent of interest. By virtue of binding to long-lived blood components, the half-life of the agent of interest is greatly extended in vivo.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 15, 2000
    Assignee: Conjuchem, Inc.
    Inventors: Philippe Pouletty, Christine Pouletty
  • Patent number: RE36866
    Abstract: The present invention provides a novel anti-AIDS immunotoxin. The immunotoxin comprises a toxin chemically conjugated to a monoclonal antibody directed against viral reverse transcriptase. Also provided are various methods of using this novel immunotoxin including methods of treating various diseases.
    Type: Grant
    Filed: July 2, 1998
    Date of Patent: September 12, 2000
    Assignee: Research Development Foundation
    Inventor: George Barrie Kitto